The FDA grants priority review to Bayer's (BAYRY.PK) and J&J's (JNJ) blood-clotting...

|About: Bayer A.G. ADR (BAYRY)|By:, SA News Editor

The FDA grants priority review to Bayer's (BAYRY.PK) and J&J's (JNJ) blood-clotting treatment Xarelto for use against deep vein thrombosis and pulmonary embolism, and the prevention of venous thromboembolism in people who have already had it. However, Bayer withdraws its request to use Xarelto to lower the risk of blood clots in heart-stent patients.